Kiniksa Pharmaceuticals International, plc (KNSA) financials: revenue, earnings and cash flow
Fiscal 2017–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Net income in fiscal 2025 was $59M, a net margin of 8.7%; the best year in this period was 2022 with $183M.
Over the twelve months to September 30, 2026, revenue was $946M and net income $110M.
Free cash flow was $136M in fiscal 2025 and positive in 4 of the 9 years shown.
The diluted share count rose 4264% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $946M | $678M | $423M | $270M | $220M | $39M | — | — | — | — |
| Gross profit | $853M | $600M | $362M | $237M | $197M | $29M | — | — | — | — |
| Operating income | $130M | $77M | -$46M | -$25M | $10M | -$157M | -$157M | -$170M | -$108M | -$65M |
| Net income | $110M | $59M | -$43M | $14M | $183M | -$158M | -$161M | -$162M | -$103M | -$65M |
| EPS (diluted) | $1.31 | $0.75 | $-0.60 | $0.20 | $2.60 | $-2.30 | $-2.61 | $-2.99 | $-3.49 | $-35.85 |
| R&D | $136M | $97M | $112M | $76M | $65M | $99M | $112M | $135M | $87M | $56M |
| Revenue growth | — | +60.1% | +56.6% | +22.7% | +471.2% | — | — | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $199M | $138M | $26M | $13M | $6M | -$126M | -$137M | -$158M | -$81M | -$50M |
| Capital spending | -$2M | -$2M | -$277000 | -$130000 | -$105000 | -$415000 | -$283000 | -$3M | -$5M | -$69000 |
| Free cash flow | $197M | $136M | $25M | $13M | $6M | -$127M | -$137M | -$162M | -$86M | -$50M |
| Dividends paid | — | $0 | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $45M | $37M | $31M | $27M | $25M | $25M | $21M | $15M | $6M | $897000 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $414M | $244M | $206M | $191M | $182M | $323M | $233M | $307M | $46M |
| Debt | — | $9M | $10M | $12M | $6M | $6M | $7M | $3M | $0 | $0 |
| Equity | — | $568M | $438M | $439M | $396M | $185M | $312M | $225M | $279M | -$90M |
| Total assets | — | $764M | $581M | $526M | $460M | $233M | $349M | $255M | $322M | $47M |
| Shares (diluted) | 85M | 79M | 71M | 72M | 70M | 69M | 62M | 54M | 30M | 2M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 90.2% | 88.5% | 85.6% | 87.6% | 89.6% | 76.4% | — | — | — | — |
| Operating margin | 13.8% | 11.4% | -10.8% | -9.3% | 4.4% | -406.4% | — | — | — | — |
| Net margin | 11.6% | 8.7% | -10.2% | 5.2% | 83.3% | -409.7% | — | — | — | — |
| FCF margin | 20.8% | 20.1% | 6.0% | 4.9% | 2.6% | -328.8% | — | — | — | — |
| ROIC | — | 8.9% | -8.0% | -4.4% | 1.9% | -64.8% | -39.0% | -73.6% | -38.6% | — |
| ROE | — | 10.4% | -9.8% | 3.2% | 46.3% | -85.4% | -51.7% | -71.8% | -37.0% | 72.3% |
Frequently asked questions
What is Kiniksa Pharmaceuticals International’s annual revenue?
$678M in fiscal 2025 and $946M over the twelve months to September 30, 2026.
How much profit does Kiniksa Pharmaceuticals International make?
Net income was $59M in fiscal 2025 (net margin 8.7%).
Is Kiniksa Pharmaceuticals International’s revenue growing?
Yes: revenue rose 60.1% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.